A new generation of technology for the next generation of diagnostics.

We are developing a new generation of technology to break existing diagnostic barriers.

Our goal is to empower very early screening of genetic and infectious diseases. By lowering the detection limit of rare mutations and pathogens, we are looking to catch diseases while they are still treatable. Our assay technology platforms will enable sensitive, rapid, and affordable point-of-care testing.

Bridge.jpg

About

Read more about the history of the company and our mission.

Planning2.jpeg

Projects

Learn more about our current projects and areas of focus.

Featured
National Cancer Prevention and Early Detection Month
National Cancer Prevention and Early Detection Month

April marks National Cancer Prevention and Early Detection Month - a time to emphasize the critical role early detection of cancer plays in improving therapeutic outcomes and survival rates. At @GenEndeavor, we're dedicated to advancing our mission of creating diagnostic tools for the early detection of ovarian cancer. We are uniting a consortium of global partners who share our vision for developing an accessible diagnostic tool specifically tailored for early detection of ovarian cancer. Let's join forces to drive meaningful progress in the battle against ovarian cancer!

Read More →
Radio Interview with Ricardo Mancebo

Radio interview with GenEndeavor Founder & CEO Ricardo Mancebo at the BIO CEO & Investor Conference in New York City that aired on March 11, 2024. Courtesy of "Community Matters" Host, Jonjy Ananth and Co-host, Uma Ananth

Read More →
Alina Nalyvayko joins GenEndeavor!
Alina Nalyvayko joins GenEndeavor!

GenEndeavor is delighted to announce the addition of Alina Nalyvayko to our team! Previously, Alina served as a Staff Research Associate at the Department of Experimental Medicine at UCSF and brings her expertise in Molecular Biology and m.TB research to GENENDEAVOR LLC to explore and advance accessible diagnostic solutions for TB patients.

Read More →
GenEndeavor to attend the BIO-Europe Spring Conference, March 19, 2024

We are thrilled to announce @GenEndeavor will be presenting at the upcoming BIO-Europe Spring Conference in Barcelona, Spain on March 19, 2024.
 
At the event, GenEndeavor will showcase our Non-Enzymatic Amplification Technologies (NEAT) platform to usher in a new generation of technologies for molecular diagnostics.

Read More →
Brindhi Amalraj joins GenEndeavor
Brindhi Amalraj joins GenEndeavor

"Joining GenEndeavor fills me with excitement as I look forward to immersing myself in molecular diagnostics and making significant contributions to tackling practical challenges." - Brindhi Amalraj

Read More →
GenEndeavor attending the BIO CEO & Investor Conference, NY 2/26 & 2/27

We are thrilled to announce @GenEndeavor’s participation in the upcoming BIO CEO & Investor Conference, in New York City, NY, on February 26-27, 2024.
 
At the event, GenEndeavor will showcase our Non-Enzymatic Amplification Technologies (NEAT) platform to usher in a new generation of technologies for molecular diagnostics.

Read More →
Commitment to Early Detection: Chris Evert’s story

Despite some incredible progress made in cancer research in the last several years, sadly, advanced stage ovarian cancer still results in a 17% survival rate.  This means that there are no screening tests available for the nearly 4 billion women in the world. 

Read More →
Year-end thoughts

As we approach the end of the year, we at @GenEndeavor continue to think about the challenges that persist in women's healthcare. Despite some incredible progress made in cancer research, sadly, advanced stage ovarian cancer still results in a 17% survival rate. 

Read More →
GenEndeavor attending the New England Venture Summit Dec. 12 & 13, 2023
Read More →

Want to stay updated on GenEndeavor news? Join our mailing list.

* indicates required